Randomized Trialvery high evidence
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lancet (London, England)·September 9, 2026·PMID 42716074
Why it mattersResectable gastric and gastro-oesophageal junction adenocarcinoma carries a high risk of recurrence and death despite perioperative chemotherapy. This trial provides the first phase 3 evidence that adding an immune checkpoint inhibitor to standard FLOT improves overall survival, establishing a new treatment option for these patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled